Tremfya’s durable remission rates shown in UC trial

US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced that the Tremfya (guselkumab) QUASAR maintenance study in ulcerative colitis (UC) met its primary endpoint and all major secondary endpoints, including highly statistically-significant rates of endoscopic remission.

Exactly 50% percent of patients with moderately to severely active UC receiving subcutaneous (SC) Tremfya 200mg every four weeks and 45.2% of those given SC Tremfya 100mg every eight weeks achieved the primary endpoint of clinical remission, at week 44 compared to placebo (18.9 %1).

In additional analyses of patients who were in clinical remission, 67% and 71%, respectively, were also in endoscopic remission at week 44, indicating they had normal appearance of intestinal mucosa.